JPWO2020118114A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020118114A5 JPWO2020118114A5 JP2021531034A JP2021531034A JPWO2020118114A5 JP WO2020118114 A5 JPWO2020118114 A5 JP WO2020118114A5 JP 2021531034 A JP2021531034 A JP 2021531034A JP 2021531034 A JP2021531034 A JP 2021531034A JP WO2020118114 A5 JPWO2020118114 A5 JP WO2020118114A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- effective amount
- empagliflozin
- methanone
- benzofuran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3,5-dibromo-4-hydroxyphenyl Chemical group 0.000 claims 4
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 3
- 201000005569 Gout Diseases 0.000 claims 2
- 201000001431 Hyperuricemia Diseases 0.000 claims 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims 2
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims 2
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims 2
- UBVZQGOVTLIHLH-UHFFFAOYSA-N 4-[5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl]-pyridine-2-carbonitrile Chemical compound C1=NC(C#N)=CC(C=2N=C(NN=2)C=2C=CN=CC=2)=C1 UBVZQGOVTLIHLH-UHFFFAOYSA-N 0.000 claims 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- 229960003459 allopurinol Drugs 0.000 claims 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical group OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 1
- 229960001713 canagliflozin Drugs 0.000 claims 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims 1
- 229960003834 dapagliflozin Drugs 0.000 claims 1
- 229940111430 dapagliflozin / metformin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003345 empagliflozin Drugs 0.000 claims 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 claims 1
- 229940117524 empagliflozin / linagliptin Drugs 0.000 claims 1
- 229940002735 empagliflozin / metformin Drugs 0.000 claims 1
- 229960005101 febuxostat Drugs 0.000 claims 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229950004176 topiroxostat Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776251P | 2018-12-06 | 2018-12-06 | |
| US62/776,251 | 2018-12-06 | ||
| PCT/US2019/064785 WO2020118114A1 (en) | 2018-12-06 | 2019-12-05 | Methods for treating or preventing gout or hyperuricemia |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022510303A JP2022510303A (ja) | 2022-01-26 |
| JPWO2020118114A5 true JPWO2020118114A5 (https=) | 2022-12-12 |
| JP2022510303A5 JP2022510303A5 (https=) | 2022-12-12 |
| JP7528080B2 JP7528080B2 (ja) | 2024-08-05 |
Family
ID=70974386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531034A Active JP7528080B2 (ja) | 2018-12-06 | 2019-12-05 | 痛風または高尿酸血症を処置または予防するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12419854B2 (https=) |
| EP (1) | EP3890722A4 (https=) |
| JP (1) | JP7528080B2 (https=) |
| CN (1) | CN113164439A (https=) |
| AU (1) | AU2019392750B2 (https=) |
| BR (1) | BR112021010720A2 (https=) |
| CA (1) | CA3121624A1 (https=) |
| EA (1) | EA202191543A1 (https=) |
| IL (1) | IL283665A (https=) |
| SG (1) | SG11202105743RA (https=) |
| TW (1) | TW202038936A (https=) |
| WO (1) | WO2020118114A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3484862B1 (en) | 2016-07-18 | 2021-09-01 | Arthrosi Therapeutics, Inc. | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia |
| SG11202105743RA (en) | 2018-12-06 | 2021-06-29 | Arthrosi Therapeutics Inc | Methods for treating or preventing gout or hyperuricemia |
| KR102946486B1 (ko) | 2018-12-06 | 2026-03-31 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
| CN113368032A (zh) * | 2020-07-23 | 2021-09-10 | 太阳升(亳州)生物医药科技有限公司 | 药物组合物、口服固体制剂及其制备方法和用途 |
| TW202330485A (zh) * | 2021-12-02 | 2023-08-01 | 美商安索治療公司 | 用於治療或預防痛風或高尿酸血症之化合物的結晶形式 |
| WO2023125667A1 (en) * | 2021-12-30 | 2023-07-06 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| KR0182801B1 (ko) | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
| CZ282760B6 (cs) | 1991-11-22 | 1997-09-17 | Procter And Gamble Pharmaceuticals, Inc. | Risedronátové prostředky se zpožděným uvolňováním |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE69332291T2 (de) | 1992-10-16 | 2003-07-31 | Nippon Shinyaku Co., Ltd. | Verfahren zur herstellung von wachsmatrizes |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| DE19624292A1 (de) | 1996-06-18 | 1998-01-02 | Merckle Gmbh | Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| WO2005121112A1 (ja) | 2004-06-10 | 2005-12-22 | Torii Pharmaceutical Co., Ltd. | ６－ヒドロキシベンズブロマロン又はその塩からなる医薬組成物 |
| US20080305169A1 (en) | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
| CN101765582A (zh) | 2007-04-26 | 2010-06-30 | 奥斯拜客斯制药有限公司 | 氘标记的氯胺酮 |
| US8791077B2 (en) * | 2008-05-22 | 2014-07-29 | Astrazeneca Ab | Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same |
| JP5325065B2 (ja) | 2009-09-30 | 2013-10-23 | 株式会社富士薬品 | 新規フェノール誘導体 |
| IT1400609B1 (it) * | 2010-05-10 | 2013-06-14 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e metformina e loro uso. |
| US10005750B2 (en) | 2010-10-06 | 2018-06-26 | J-Pharma Co., Ltd. | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action |
| US20150031768A1 (en) | 2011-08-19 | 2015-01-29 | The Trustees Of Princeton University | C-halogen bond formation |
| US9060987B2 (en) | 2011-11-04 | 2015-06-23 | Cymabay Therapeutics, Inc. | Methods for treating gout flares |
| US9962362B2 (en) | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| WO2013152860A2 (en) | 2012-04-11 | 2013-10-17 | Dutalys Gmbh | Improved antibody light chains |
| JO3754B1 (ar) | 2012-06-04 | 2021-01-31 | Pharmacyclics Llc | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون |
| CN104717980A (zh) | 2012-08-14 | 2015-06-17 | 米纳瓦生物技术公司 | 干细胞增强疗法 |
| JP2016500367A (ja) | 2012-12-05 | 2016-01-12 | デュタリス ゲーエムベーハー | デュアルターゲティング |
| WO2014113407A2 (en) | 2013-01-16 | 2014-07-24 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting eya tyrosine phosphatase |
| WO2014149789A1 (en) | 2013-03-15 | 2014-09-25 | Janssen Pharmaceutica Nv | Combination of canagliflozin and probenecid for the treament of hyperuricemia |
| WO2014194226A2 (en) | 2013-05-31 | 2014-12-04 | Takeda Pharmaceuticals U.S.A., Inc. | Methods of treatment and compositions with xanthine oxidase inhibitors |
| WO2015134467A1 (en) | 2014-03-05 | 2015-09-11 | The Trustees Of Princeton University | Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks |
| CN107001356B (zh) | 2014-07-31 | 2019-09-03 | 默克专利有限公司 | 用于神经退化性疾病的中氮茚衍生物 |
| CN104262305B (zh) | 2014-09-16 | 2016-06-08 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型a及其制备方法 |
| CN104311516B (zh) | 2014-09-16 | 2017-01-11 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型b及其制备方法 |
| EP3484862B1 (en) * | 2016-07-18 | 2021-09-01 | Arthrosi Therapeutics, Inc. | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia |
| WO2018090921A1 (zh) | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| KR101964435B1 (ko) | 2016-12-14 | 2019-04-01 | 주식회사 엘지화학 | 헤테로 고리 화합물 및 이를 포함하는 유기 발광 소자 |
| US20210130312A1 (en) | 2018-04-03 | 2021-05-06 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
| MX2021003845A (es) | 2018-10-01 | 2021-05-27 | Astrazeneca Ab | Composiciones para reducir el acido urico serico. |
| SG11202105743RA (en) | 2018-12-06 | 2021-06-29 | Arthrosi Therapeutics Inc | Methods for treating or preventing gout or hyperuricemia |
| KR102946486B1 (ko) | 2018-12-06 | 2026-03-31 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
| WO2020232156A1 (en) | 2019-05-14 | 2020-11-19 | Arthrosi Therapeutics, Inc. | Compound for treating gout or hyperuricemia |
| CN112952564B (zh) | 2019-12-25 | 2022-04-22 | 华为数字能源技术有限公司 | 配电模块及通信电源系统 |
| KR20230024354A (ko) | 2020-06-10 | 2023-02-20 | 아쓰로시 테라퓨틱스, 인크. | 만성 신장 질환을 치료 또는 예방하는 방법 |
| CN112729156A (zh) | 2020-12-24 | 2021-04-30 | 上海智能制造功能平台有限公司 | 一种人体数字化测量装置的数据拼接及系统标定方法 |
| CN114697265A (zh) | 2020-12-29 | 2022-07-01 | 华为技术服务有限公司 | 一种报文处理方法及装置 |
| TW202330485A (zh) | 2021-12-02 | 2023-08-01 | 美商安索治療公司 | 用於治療或預防痛風或高尿酸血症之化合物的結晶形式 |
| WO2023125667A1 (en) | 2021-12-30 | 2023-07-06 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
-
2019
- 2019-12-05 SG SG11202105743RA patent/SG11202105743RA/en unknown
- 2019-12-05 BR BR112021010720-7A patent/BR112021010720A2/pt unknown
- 2019-12-05 EA EA202191543A patent/EA202191543A1/ru unknown
- 2019-12-05 WO PCT/US2019/064785 patent/WO2020118114A1/en not_active Ceased
- 2019-12-05 JP JP2021531034A patent/JP7528080B2/ja active Active
- 2019-12-05 AU AU2019392750A patent/AU2019392750B2/en active Active
- 2019-12-05 CN CN201980080586.8A patent/CN113164439A/zh active Pending
- 2019-12-05 CA CA3121624A patent/CA3121624A1/en active Pending
- 2019-12-05 EP EP19891796.5A patent/EP3890722A4/en active Pending
- 2019-12-05 US US17/311,245 patent/US12419854B2/en active Active
- 2019-12-06 TW TW108144816A patent/TW202038936A/zh unknown
-
2021
- 2021-06-02 IL IL283665A patent/IL283665A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9526728B2 (en) | Medical use of a DPP-4 inhibitor | |
| AU2020204571A1 (en) | Pyrazole derivatives as sGC stimulators | |
| KR20220026538A (ko) | 코로나바이러스 및 피코르나바이러스 감염 치료용 펩티도모방체 | |
| NO2008013I2 (no) | Sitagliptin, eventuelt i form av et farmasøytisk akseptabelt salt, særlig monofosfatet, pluss metformin hydroklorid. | |
| WO2005082863A3 (en) | 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors | |
| US20070093492A1 (en) | Pyrrolidine derivatives | |
| CN102666541A (zh) | 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物 | |
| CA2341970A1 (en) | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | |
| WO2001012189A1 (en) | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents | |
| JP2021522247A5 (https=) | ||
| JP2024028337A5 (https=) | ||
| JPWO2020118114A5 (https=) | ||
| US12162857B2 (en) | Antiviral compounds | |
| JP2003502367A5 (https=) | ||
| PE20230859A1 (es) | Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina | |
| EP3820470B1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators for use in treating portal hypertension | |
| RU2007101238A (ru) | Пептидные агонисты вазопрессинового рецептора | |
| JP2018502911A5 (https=) | ||
| US9371307B2 (en) | Serine protease inhibitors | |
| KR20230048517A (ko) | 베타 코로나바이러스 감염과 연관된 질환을 치료 또는 예방하기 위한 조성물 및 방법 | |
| US20040198741A1 (en) | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | |
| JP2003522171A5 (https=) | ||
| WO2008033754A3 (en) | Xanthine derivatives in methods and compositions for the treatment of vascular depression | |
| WO2015105195A1 (ja) | 肺高血圧症治療薬 | |
| WO2004037166A3 (en) | Therapeutic guanidines |